AMP Stock Analysis: Amplifon S.p.A | MI
Medical Distribution | MI, Italy | Market Cap: 3.095m EUR | 12M Return: -16.1% | IT0004056880 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 10.9M
EPS Trend: -71.9%
Qual. Beats: 0
Rev. Trend: 81.4%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Amplifon S.p.A. is a global distributor of hearing solutions and customized hearing products, operating across Europe, the Middle East, Africa, the Americas, and the Asia Pacific. Founded in 1950 and headquartered in Milan, Italy, the company supports customers through audiological care services (Ampli-care), a smartphone application for device management, and proprietary product lines such as Ampli-power and Ampli-mini hearing devices.
As classified under the GICS Health Care Distributors sub-industry, Amplifons business model is primarily retail-driven rather than manufacturing-focused, with revenue generated through the sale and fitting of hearing aids and related audiology services to end consumers. The hearing solutions market is shaped by demographic trends such as an aging population, and hearing aids are typically classified as regulated medical devices subject to national healthcare reimbursement schemes in many of the companys operating regions.
- Aging demographics globally drive structural hearing aid demand growth
- Americas and Asia Pacific organic growth outpaces mature European core market
- M&A pipeline and store expansion fuel top-line and margin scaling
| Net Income: 72.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 1.30 > 1.0 |
| NWC/Revenue: -12.41% < 20% (prev -17.99%; Δ 5.58% < -1%) |
| CFO/TA 0.06 > 3% & CFO 205.4m > Net Income 72.3m |
| Net Debt (849.3m) to EBITDA (509.4m): 1.67 < 3 |
| Current Ratio: 0.60 > 1.5 & < 3 |
| Outstanding Shares: last quarter (271.7m) vs 12m ago 20.01% < -2% |
| Gross Margin: 8.59% > 18% (prev 56.45%; Δ -47.86% > 0.5%) |
| Asset Turnover: 64.35% > 50% (prev 62.59%; Δ 1.76% > 0%) |
| Interest Coverage Ratio: 3.42 > 6 (EBIT TTM 202.1m / Interest Expense TTM 59.1m) |
| A: -0.08 (Total Current Assets 440.2m - Total Current Liabilities 738.2m) / Total Assets 3.60b |
| B: 0.30 (Retained Earnings 1.08b / Total Assets 3.60b) |
| C: 0.05 (EBIT TTM 202.1m / Avg Total Assets 3.73b) |
| D: 0.73 (Book Value of Equity 1.51b / Total Liabilities 2.09b) |
| Altman-Z'' = 1.56 = BB |
| DSRI: 1.08 (Receivables 360.4m/335.0m, Revenue 2.40b/2.42b) |
| GMI: 6.57 (GM 56.45% / 8.59%) |
| AQI: 1.08 (AQ_t 0.69 / AQ_t-1 0.64) |
| SGI: 0.99 (Revenue 2.40b / 2.42b) |
| TATA: -0.04 (NI 72.3m - CFO 205.4m) / TA 3.60b) |
| Beneish M = 2.13 (Cap -4..+1) = D |
As of September 27, 2026, the stock is trading at EUR 11.43 with a total of 1,074,733 shares traded. Over the past week, the price has changed by +0.26%, over one month by -3.67%, over three months by +13.17% and over the past year by -16.08%.
Current recommended Stop Loss: 10.80 (which is 5.5% or 2.2 ATR below the current price).
Amplifon S.p.A has no consensus analysts rating.
P/E Trailing = 37.5645
P/E Forward = 11.9048
P/S = 1.2889
P/B = 2.0277
P/EG = 0.3398
Revenue TTM = 2.40b EUR
EBIT TTM = 202.1m EUR
EBITDA TTM = 509.4m EUR
Long Term Debt = 567.8m EUR (from longTermDebt, last quarter)
Short Term Debt = 25.7m EUR (from shortTermDebt, last quarter)
Debt = 1.56b EUR (from shortLongTermDebtTotal, last quarter) + Leases 483.9m
Net Debt = 849.3m EUR (calculated: Debt 1.56b - CCE 712.8m)
Enterprise Value = 3.94b EUR (3.09b + Debt 1.56b - CCE 712.8m)
Interest Coverage Ratio = 3.42 (Ebit TTM 202.1m / Interest Expense TTM 59.1m)
EV/FCF = 11.49x (Enterprise Value 3.94b / FCF TTM 343.3m)
FCF Yield = 8.70% (FCF TTM 343.3m / Enterprise Value 3.94b)
FCF Margin = 14.30% (FCF TTM 343.3m / Revenue TTM 2.40b)
Net Margin = 3.01% (Net Income TTM 72.3m / Revenue TTM 2.40b)
Gross Margin = 8.59% ((Revenue TTM 2.40b - Cost of Revenue TTM 2.19b) / Revenue TTM)
Gross Margin QoQ = 11.17% (prev 11.02%)
Tobins Q-Ratio = 1.10 (Enterprise Value 3.94b / Total Assets 3.60b)
Interest Expense / Debt = 3.79% (Interest Expense 59.1m / Debt 1.56b)
Taxrate = 34.10% (37.5m / 110.0m)
NOPAT = 133.2m (EBIT 202.1m * (1 - 34.10%))
Current Ratio = 0.60 (Total Current Assets 440.2m / Total Current Liabilities 738.2m)
Debt / Equity = 1.03 (Debt 1.56b / totalStockholderEquity, last quarter 1.51b)
Debt / EBITDA = 1.67 (Net Debt 849.3m / EBITDA 509.4m)
Debt / FCF = 2.47 (Net Debt 849.3m / FCF TTM 343.3m)
Total Stockholder Equity = 1.14b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.94% (Net Income 72.3m / Total Assets 3.60b)
RoE = 6.34% (Net Income TTM 72.3m / Total Stockholder Equity 1.14b)
RoCE = 11.84% (EBIT 202.1m / Capital Employed (Equity 1.14b + L.T.Debt 567.8m))
RoIC = 4.81% (NOPAT 133.2m / Invested Capital 2.77b)
WACC = 7.42% (E(3.09b)/V(4.66b) * Re(9.91%) + D(1.56b)/V(4.66b) * Rd(3.79%) * (1-Tc(0.34)))
Discount Rate = 9.91% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 49.96 | Cagr: 8.27%
[DCF] Terminal Value 76.42% ; FCFF base≈333.3m ; Y1≈356.4m ; Y5≈428.3m
[DCF] Fair Price = 21.55 (EV 6.58b - Net Debt 849.3m = Equity 5.73b / Shares 265.7m; r=8.35% [WACC [floored]]; 5y FCF grow 7.86% → 2.50% )
EPS Correlation: -71.86 | EPS CAGR: -7.21% | SUE: 0.19 | # QB: 0
Revenue Correlation: 81.40 | Revenue CAGR: 2.68% | SUE: -0.02 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.10 | Chg30d=-5.04% | Revisions=-25% | Analysts=2
EPS current Year (2026-12-31): EPS=0.72 | Chg30d=+2.93% | Revisions=+30% | GrowthEPS=+0.7% | GrowthRev=+1.5%
EPS next Year (2027-12-31): EPS=0.88 | Chg30d=+0.74% | Revisions=+70% | GrowthEPS=+22.3% | GrowthRev=+43.6%
[Analyst] Revisions Ratio: +50% (up=12, down=3)